US Patent 10758497 Treatment of fragile x syndrome with cannabidiol
Patent 10758497 was granted and assigned to Zynerba Pharmaceuticals on September, 2020 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 10758497 Treatment of fragile x syndrome with cannabidiol
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
